The $165M im­munol­o­gy start­up Sheila Gu­jrathi bet on af­ter Re­cep­tos, Gos­samer is shoot­ing for an IPO

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Sheila Gu­jrathi has kept her­self busy since leav­ing the helm of Gos­samer Bio in the af­ter­math of a mid-stage flop. She signed on to a few biotech boards, most re­cent­ly to be­come Ven­tyx Bio’s ex­ec­u­tive chair.

But it turns out her con­nec­tion with the biotech runs much deep­er. As Ven­tyx re­vealed in its S-1, Gu­jrathi made a small in­vest­ment in the com­pa­ny dur­ing the Se­ries A — which took place be­tween Feb­ru­ary and June 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER